Literature DB >> 15671147

Stem cell factor synergistically enhances thrombopoietin-induced STAT5 signaling in megakaryocyte progenitors through JAK2 and Src kinase.

A Lyndsay Drayer1, Arjen-Kars Boer, E Leonie Los, Mariet T Esselink, Edo Vellenga.   

Abstract

Stem cell factor (SCF) has a potent synergistic effect during megakaryopoiesis when administered in combination with the major megakaryocytic cytokine, thrombopoietin (TPO). In this study we analyzed the underlying mechanisms with regard to STAT5 activity. TPO stimulation of MO7e cells resulted in STAT5 transactivation, which could be enhanced 1.6-fold by costimulation with SCF, whereas SCF alone did not induce STAT5 transcriptional activity. This costimulatory effect of SCF was reflected in an increase in TPO-induced STAT5 DNA binding and increased and prolonged STAT5 tyrosine phosphorylation in both MO7e cells and primary human megakaryocyte progenitors. In contrast, serine phosphorylation of STAT5 was constitutive and associated with an inhibitory effect on STAT5 transactivation. Signal transduction pathways that might synergize in TPO-mediated STAT5 transactivation were analyzed using specific pharmacological inhibitors and indicated an essential role for Janus-activated kinase 2 (JAK2) and a partial role for Src-family kinases. Costimulation with SCF was found to increase and prolong tyrosine phosphorylation of JAK2 and the TPO receptor c-mpl. In addition, the Src kinase inhibitor SU6656 partially downregulated the additional effect of SCF costimulation on STAT5 tyrosine phosphorylation. SCF-induced enhancement of JAK2 phosphorylation was not affected by inhibition of Src kinase, suggesting that both JAK2 and Src kinase mediate STAT5 tyrosine phosphorylation. Synergistic activation of JAK2 and Src kinase may thus contribute to the enhanced STAT5 signaling in the presence of TPO and SCF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15671147     DOI: 10.1634/stemcells.2004-0153

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  9 in total

1.  Lyn kinase promotes erythroblast expansion and late-stage development.

Authors:  Vinit G Karur; Clifford A Lowell; Peter Besmer; Valter Agosti; Don M Wojchowski
Journal:  Blood       Date:  2006-05-16       Impact factor: 22.113

2.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

3.  Enhancing functional platelet release in vivo from in vitro-grown megakaryocytes using small molecule inhibitors.

Authors:  Danuta Jarocha; Karen K Vo; Randolph B Lyde; Vincent Hayes; Rodney M Camire; Mortimer Poncz
Journal:  Blood Adv       Date:  2018-03-27

4.  Role of retinoic acid and platelet-derived growth factor receptor cross talk in the regulation of neonatal gonocyte and embryonal carcinoma cell differentiation.

Authors:  Gurpreet Manku; Yan Wang; Vanessa Merkbaoui; Annie Boisvert; Xiaoying Ye; Josip Blonder; Martine Culty
Journal:  Endocrinology       Date:  2015-01       Impact factor: 4.736

Review 5.  Challenges and promises for the development of donor-independent platelet transfusions.

Authors:  Michele P Lambert; Spencer K Sullivan; Rudy Fuentes; Deborah L French; Mortimer Poncz
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

6.  Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism.

Authors:  N Théou-Anton; S Tabone; D Brouty-Boyé; R Saffroy; L Ronnstrand; A Lemoine; J-F Emile
Journal:  Br J Cancer       Date:  2006-04-24       Impact factor: 7.640

7.  Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses.

Authors:  Lina Han; Albertus T J Wierenga; Marjan Rozenveld-Geugien; Kim van de Lande; Edo Vellenga; Jan Jacob Schuringa
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

8.  Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.

Authors:  Iván Parra-Izquierdo; Alexander R Melrose; Jiaqing Pang; Hari Hara Sudhan Lakshmanan; Stéphanie E Reitsma; Sai Hitesh Vavilapalli; Mark K Larson; Joseph J Shatzel; Owen J T McCarty; Joseph E Aslan
Journal:  Platelets       Date:  2021-06-07       Impact factor: 4.236

9.  PTPN13 and β-Catenin Regulate the Quiescence of Hematopoietic Stem Cells and Their Interaction with the Bone Marrow Niche.

Authors:  Guillermo López-Ruano; Rodrigo Prieto-Bermejo; Teresa L Ramos; Laura San-Segundo; Luis Ignacio Sánchez-Abarca; Fermín Sánchez-Guijo; José Antonio Pérez-Simón; Jesús Sánchez-Yagüe; Marcial Llanillo; Ángel Hernández-Hernández
Journal:  Stem Cell Reports       Date:  2015-09-03       Impact factor: 7.765

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.